BRPI0408186A - derivados de 2-(diaza-biciclo-alquil)-pirimidona substituìdos - Google Patents
derivados de 2-(diaza-biciclo-alquil)-pirimidona substituìdosInfo
- Publication number
- BRPI0408186A BRPI0408186A BRPI0408186-2A BRPI0408186A BRPI0408186A BR PI0408186 A BRPI0408186 A BR PI0408186A BR PI0408186 A BRPI0408186 A BR PI0408186A BR PI0408186 A BRPI0408186 A BR PI0408186A
- Authority
- BR
- Brazil
- Prior art keywords
- group
- ring
- alkyl
- diaza
- optionally substituted
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
- 102000001267 GSK3 Human genes 0.000 abstract 1
- 108060006662 GSK3 Proteins 0.000 abstract 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical group C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03290570A EP1454910A1 (en) | 2003-03-07 | 2003-03-07 | Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
| EP20030290571 EP1454908B1 (en) | 2003-03-07 | 2003-03-07 | Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives |
| PCT/EP2004/003050 WO2004078759A1 (en) | 2003-03-07 | 2004-03-05 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0408186A true BRPI0408186A (pt) | 2006-04-04 |
Family
ID=32963795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0408186-2A BRPI0408186A (pt) | 2003-03-07 | 2004-03-05 | derivados de 2-(diaza-biciclo-alquil)-pirimidona substituìdos |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7211581B2 (https=) |
| EP (1) | EP1603910B1 (https=) |
| JP (1) | JP4778890B2 (https=) |
| KR (1) | KR101072159B1 (https=) |
| AR (1) | AR043486A1 (https=) |
| AT (1) | ATE440844T1 (https=) |
| AU (1) | AU2004218249B2 (https=) |
| BR (1) | BRPI0408186A (https=) |
| CA (1) | CA2516934C (https=) |
| CY (1) | CY1111132T1 (https=) |
| DE (1) | DE602004022784D1 (https=) |
| DK (1) | DK1603910T3 (https=) |
| EA (1) | EA008595B1 (https=) |
| ES (1) | ES2332132T3 (https=) |
| IL (1) | IL170468A (https=) |
| MX (1) | MXPA05009575A (https=) |
| NO (1) | NO20054141L (https=) |
| NZ (1) | NZ542136A (https=) |
| PL (1) | PL1603910T3 (https=) |
| PT (1) | PT1603910E (https=) |
| SI (1) | SI1603910T1 (https=) |
| WO (1) | WO2004078759A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200813015A (en) * | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
| EP1992620A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases |
| EP1992621A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases |
| EP1992624A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
| EP1992625A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994460A (en) * | 1989-06-01 | 1991-02-19 | Bristol-Myers Squibb Co. | Agents for treatment of brain ischemia |
| US5883254A (en) * | 1996-11-08 | 1999-03-16 | Hoffmann-La Roche Inc. | Process for making pyrimidine derivatives |
| AU2001262150A1 (en) * | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(nitrogen-heterocyclic)pyrimidone derivatives |
| EP1136483A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperazinyl]pyrimidone derivatives |
| DE60302221T2 (de) * | 2002-02-28 | 2006-08-03 | Sanofi-Aventis | Heteroaryl substituierte 2-pyridinyl und 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-onderivate |
-
2004
- 2004-03-05 PT PT04717644T patent/PT1603910E/pt unknown
- 2004-03-05 AT AT04717644T patent/ATE440844T1/de active
- 2004-03-05 BR BRPI0408186-2A patent/BRPI0408186A/pt not_active IP Right Cessation
- 2004-03-05 AU AU2004218249A patent/AU2004218249B2/en not_active Ceased
- 2004-03-05 CA CA2516934A patent/CA2516934C/en not_active Expired - Fee Related
- 2004-03-05 SI SI200431263T patent/SI1603910T1/sl unknown
- 2004-03-05 AR ARP040100695A patent/AR043486A1/es not_active Application Discontinuation
- 2004-03-05 NZ NZ542136A patent/NZ542136A/en not_active IP Right Cessation
- 2004-03-05 ES ES04717644T patent/ES2332132T3/es not_active Expired - Lifetime
- 2004-03-05 PL PL04717644T patent/PL1603910T3/pl unknown
- 2004-03-05 WO PCT/EP2004/003050 patent/WO2004078759A1/en not_active Ceased
- 2004-03-05 DK DK04717644T patent/DK1603910T3/da active
- 2004-03-05 EA EA200501243A patent/EA008595B1/ru not_active IP Right Cessation
- 2004-03-05 JP JP2006504812A patent/JP4778890B2/ja not_active Expired - Fee Related
- 2004-03-05 EP EP04717644A patent/EP1603910B1/en not_active Expired - Lifetime
- 2004-03-05 MX MXPA05009575A patent/MXPA05009575A/es active IP Right Grant
- 2004-03-05 DE DE602004022784T patent/DE602004022784D1/de not_active Expired - Lifetime
-
2005
- 2005-08-23 IL IL170468A patent/IL170468A/en not_active IP Right Cessation
- 2005-09-06 NO NO20054141A patent/NO20054141L/no not_active Application Discontinuation
- 2005-09-06 US US11/219,923 patent/US7211581B2/en not_active Expired - Fee Related
- 2005-09-06 KR KR1020057016636A patent/KR101072159B1/ko not_active Expired - Fee Related
-
2007
- 2007-03-29 US US11/693,345 patent/US7452897B2/en not_active Expired - Fee Related
-
2009
- 2009-10-26 CY CY20091101113T patent/CY1111132T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20054141D0 (no) | 2005-09-06 |
| WO2004078759A1 (en) | 2004-09-16 |
| KR20050113218A (ko) | 2005-12-01 |
| SI1603910T1 (sl) | 2009-12-31 |
| AU2004218249B2 (en) | 2009-04-30 |
| JP4778890B2 (ja) | 2011-09-21 |
| US20070167455A1 (en) | 2007-07-19 |
| DE602004022784D1 (de) | 2009-10-08 |
| EA200501243A1 (ru) | 2006-04-28 |
| US7211581B2 (en) | 2007-05-01 |
| AR043486A1 (es) | 2005-08-03 |
| CA2516934C (en) | 2011-09-20 |
| JP2006519813A (ja) | 2006-08-31 |
| NZ542136A (en) | 2008-07-31 |
| EP1603910A1 (en) | 2005-12-14 |
| DK1603910T3 (da) | 2009-11-23 |
| PT1603910E (pt) | 2009-10-30 |
| NO20054141L (no) | 2005-12-07 |
| MXPA05009575A (es) | 2006-05-19 |
| ATE440844T1 (de) | 2009-09-15 |
| EA008595B1 (ru) | 2007-06-29 |
| HK1085742A1 (zh) | 2006-09-01 |
| AU2004218249A1 (en) | 2004-09-16 |
| IL170468A (en) | 2010-12-30 |
| EP1603910B1 (en) | 2009-08-26 |
| CY1111132T1 (el) | 2015-06-11 |
| ES2332132T3 (es) | 2010-01-27 |
| US20060025417A1 (en) | 2006-02-02 |
| US7452897B2 (en) | 2008-11-18 |
| PL1603910T3 (pl) | 2010-02-26 |
| CA2516934A1 (en) | 2004-09-16 |
| KR101072159B1 (ko) | 2011-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0417208A (pt) | derivados de 8'-piri(mi)dinil-diidroespiro-[cicloalquilamina]-pirimid o[1,2-ona]pirimidin-6-ona | |
| NO20081970L (no) | Sulfonamidderivat med PGD2-reseptorantagonistaktivitet | |
| CY1111057T1 (el) | ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ ΤΗΣ 8-ΠΥΡΙΔΙΝΥΛΟ-ΔΙΥΔΡΟΣΠΕΙΡΟ-ΚΥΚΛΟΑΛΚΥΛΟ-ΠΥΡΙΜΙΔΟ 1,2-a ΠΥΡΙΜΙΔΙΝ-6-ΟΝΗΣ ΚΑΙ ΤΗΣ 8-ΠΥΡΙΜΙΔΙΝΥΛΟ-ΔΙΥΔΡΟΣΠΕΙΡΟ-ΚΥΚΛΟΑΛΚΥΛΟ-ΠΥΡΙΜΙΔΟ 1,2-a ΠΥΡΙΜΙΔΙΝ-6- ΟΝΗΣ ΚΑΙ Η ΧΡΗΣΗ ΑΥΤΩΝ ΕΝΑΝΤΙ ΤΩΝ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΝΟΣΩΝ | |
| NO20076477L (no) | Nye heterosykliske forbindelser som positive allosteriske modulatorer av metabotrope glutamatreseptorer | |
| BRPI0509364A (pt) | derivados de tetraidroquinolina e um processo por preparar os mesmos | |
| BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda | |
| EA200970637A1 (ru) | 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы | |
| ECSP088293A (es) | Inhibidores de gamma secretasa, de sulfonamido n-cíclico puenteado | |
| BR0212896A (pt) | Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4- ona e 7-piridinil-2,3dihidroimidazo[1,2-a] pirimidin-5(1h)ona substituìdos | |
| BRPI0408605A (pt) | derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos | |
| EA200400936A1 (ru) | ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-ПИРИДИНИЛ- И 2-ПИРИМИДИНИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА | |
| AR063577A1 (es) | Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos | |
| WO2007057790A3 (en) | Substituted bicyclic pyrimidone derivatives | |
| Nowak et al. | Discovery and initial optimization of 5, 5′-disubstituted aminohydantoins as potent β-secretase (BACE1) inhibitors | |
| ATE420859T1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren | |
| BR0308106A (pt) | Derivados de 1-[alquil], 1[(heteroaril)alquil] e 1-[(aril)alquil]-7-(pirimidin-4-il)-imidazo[1,2-a]pirimidin-5- (1h)-ona | |
| WO2009041559A1 (ja) | インダゾールアクリル酸アミド化合物 | |
| BR0114424A (pt) | Derivados de 5-amidino-2-hidróxi benzeno sulfonamida, composições farmacêuticas contendo os mesmos e intermediários para a sua preparação | |
| BRPI0408186A (pt) | derivados de 2-(diaza-biciclo-alquil)-pirimidona substituìdos | |
| EA201170150A1 (ru) | Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона | |
| ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| DE60002583D1 (de) | Benzofurylpiperazine als serotonin-agonisten | |
| NO20051901L (no) | Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger | |
| AR030588A1 (es) | Derivados de 1-[alquil], 1-[(heteroaril)alquil] y 1-[(aril)alquil]-7-piridinil-imidazol[1,2-a]pirimidin-5(1h)-ona | |
| DE60329189D1 (de) | Pyrrolidinderivate als oxytocin antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014. |